Association of myelodysplastic syndrome with CD5+, CD23+ monoclonal B-cell lymphocytosis

Sandes, Alex Freire; Chauffaille, Maria de Lourdes Lopes Ferrari; Órfão, Alberto; Siufi, Grazziella Curado; Silva, Maria Regina Regis; Yamamoto, Masahiro

doi:10.6061/clinics/2012(12)22

Cited by 4 publications

(2 citation statements)

References 16 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clonal B and T cell populations have also been reported in patients with MDS with excess blast-1 66. Interestingly, the same phenomenon was demonstrated in another independent study 67.…”

Section: Neoplastic Lymphoid Aggregatessupporting

confidence: 63%

Lymphoid aggregates in bone marrow: a diagnostic pitfall

Maccio

Rets

2022

J Clin Pathol

View full text Add to dashboard Cite

Lymphoid aggregates in bone marrow specimens are a relatively frequent finding that may pose a diagnostic challenge for a pathologist. The distinction between reactive and neoplastic aggregates has significant clinical relevance. Although many testing modalities such as immunohistochemistry, flow cytometry and molecular studies are currently available in clinical laboratories, the appropriate utilisation of these modalities and the awareness of their potential pitfalls are important. When a neoplastic process is ruled out, the significance of benign lymphoid aggregates in bone marrow is often unclear, as they may be associated with a broad spectrum of conditions including infections, autoimmune disorders, medications, or may even be idiopathic.This review focuses on evidence-based criteria that can aid in making the distinction between benign and malignant lymphoid aggregates and discusses the advantages, disadvantages and limits of ancillary tests used for this purpose. Finally, the most common aetiologies of benign lymphoid aggregates and their associations with specific diseases are discussed.

show abstract

“…Clonal B and T cell populations have also been reported in patients with MDS with excess blast-1 66. Interestingly, the same phenomenon was demonstrated in another independent study 67.…”

Section: Neoplastic Lymphoid Aggregatessupporting

confidence: 63%

Lymphoid aggregates in bone marrow: a diagnostic pitfall

Maccio

Rets

2022

J Clin Pathol

View full text Add to dashboard Cite

show abstract

“…In this regard, it should be noted that occurrence of CLL in association with myeloid malignancies has been only sporadically reported (Lai et al, 1999;Barresi et al, 2000;Miller et al, 2001;Aviv et al, 2004), including cases with CLL associated with acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS) (Billstr€ om et al, 1997;Laurenti et al, 2011;Sandes et al, 2012), and/or systemic mastocytosis (Horny et al, 2006); however, no clear genetic link between the two entities has yet been identified.…”

Section: Discussionmentioning

confidence: 99%

Subjects with chronic lymphocytic leukaemia‐like B‐cell clones with stereotyped B‐cell receptors frequently show MDS‐associated phenotypes on myeloid cells

et al. 2014

Self Cite

View full text Add to dashboard Cite

SummaryAn increasing body of evidence suggests the potential occurrence of antigen encounter by the cell of origin in chronic lymphocytic leukaemia (CLL) and CLL-like monoclonal B-cell lymphocytosis (MBL). However, the scenario in which this event might occur remains unknown. In order to gain insight into this scenario we investigated the molecular, cytogenetic and haematological features of 223 CLL-like (n = 84) and CLL (n = 139) clones with stereotyped (n = 32) versus non-stereotyped (n = 191) immunoglobulin heavy chain variable region (IGHV) amino acid sequences. Overall, stereotyped CLL-like MBL and CLL clones showed a unique IGHV profile, associated with higher IGHV1 and lower IGHV3 gene family usage (P = 0Á03), longer IGHV complementary determining region 3 (HCDR3) sequences (P = 0Á007) and unmutated IGHV (P < 0Á001) versus nonstereotyped clones. Whilst the overall size of the stereotyped B-cell clones in peripheral blood did not appear to be associated with the CLL-related cytogenetic profile of B-cells (P > 0Á05), it did show a significant association with the presence of myelodysplastic syndrome (MDS)-associated immunophenotypes on peripheral blood neutrophils and/or monocytes (P = 0Á01). Altogether our results point to the potential involvement of different selection forces in the expansion of stereotyped vs. non-stereotyped CLL and CLL-like MBL clones, the former being potentially favoured by an underlying altered haematopoiesis.

show abstract

CD43 and CD49d from the B‐Cell Chronic Lymphoproliferative Disorders Diagnostic Panel Are Useful to Detect Erythroid Dysplasia

Oliveira

Laranjeira

Fortuna

et al. 2019

Cytometry Part B Clinical

View full text Add to dashboard Cite

BackgroundDespite bone marrow (BM) immunophenotyping by flow cytometry has progressively been recognized as an important tool for the diagnosis of myelodysplastic syndromes (MDS), the sparse knowledge about normal erythroid maturation and the lack of markers for erythroid characterization is a major shortcoming.MethodsHere, we analyzed the expression of CD43 and CD49d, two markers included in the diagnostic panel for B‐cell chronic lymphoproliferative disorders (B‐CLPD), in the CD34+ compartment of normal BM and along the normal and dysplastic erythroid maturation. For this, 13 normal BM aspirates and 18 BM aspirates from MDS patients were studied by flow cytometry.ResultsNormal BM presented a higher expression of CD43 and CD49d among CD34+ erythroid precursors, compared to CD34+ cells committed to the remaining hematopoietic cell lineages. CD43 expression progressively decreased along the normal erythroid maturation, whereas CD49d levels increased from Stage I to Stage II, were maintained in Stages II and III, and then decreased until the last stage of maturation. In MDS, the expression of CD43 and CD49d followed a similar pattern, but with decreased expression levels for both markers, observed in all erythroid maturation stages (P < 0.05).ConclusionsOur results point to the usefulness of CD43 and CD49d, two markers commonly present in B‐CLPD diagnosis panels, in the identification of dysplastic phenotypic features in the erythroid lineage. This allows a feasible and inexpensive way to identify patients who would benefit from a more extensive study to evaluate the presence of MDS, during the processing of suspected B‐CLPD samples. © 2019 International Clinical Cytometry Society

show abstract

Association of myelodysplastic syndrome with CD5+, CD23+ monoclonal B-cell lymphocytosis

Cited by 4 publications

References 16 publications

Lymphoid aggregates in bone marrow: a diagnostic pitfall

Lymphoid aggregates in bone marrow: a diagnostic pitfall

Subjects with chronic lymphocytic leukaemia‐like B‐cell clones with stereotyped B‐cell receptors frequently show MDS‐associated phenotypes on myeloid cells

CD43 and CD49d from the B‐Cell Chronic Lymphoproliferative Disorders Diagnostic Panel Are Useful to Detect Erythroid Dysplasia

Contact Info

Product

Resources

About